Lundbeck after record quarter: There is still uncertainty

Pharmaceutical group Lundbeck has had a great start to 2018, but uncertainty about the generic competition towards the end of the year still makes the company cautious in terms of expectations.

Photo: /Ritzau Scanpix/Jeppe Bøje Nielsen

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

David Solomon lander nyt topjob

Mindre end tre måneder efter at være trådt tilbage som adm. direktør i amerikansk biotekselskab efter kontrovers om brug af et kreditkort er den tidligere Zealand Pharma-topchef David Solomon atter tilbage i direktørstolen. Denne gang i et britisk biotekselskab.

Related articles